Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Coherent’s Mixed Signals: Record Results Met With Market Skepticism

Dieter Jaworski by Dieter Jaworski
September 12, 2025
in Analysis, Earnings, Semiconductors, TecDAX, Tech & Software
0
Coherent Stock
0
SHARES
183
VIEWS
Share on FacebookShare on Twitter

Despite posting record annual figures and securing a major strategic partnership with Apple, Coherent’s investors were left with a sense of uncertainty following its recent earnings release. The market’s reaction was decisively negative, raising questions about why a photonics leader delivering impressive results is facing such a harsh judgment.

A Cautious Outlook Overshadows Strong Performance

The market trades on future expectations, not past successes. This reality hit Coherent hard on August 13. While the company unveiled what appeared to be stellar annual results—a 23% surge in revenue to $5.81 billion and an adjusted earnings per share that nearly tripled to $3.53—its forward guidance disappointed. The company’s sales forecast for the current quarter, projected between $1.46 billion and $1.60 billion, fell short of analyst expectations. The immediate response was a swift 18% decline in after-hours trading.

Strategic Moves to Sharpen Focus

Alongside its financial data, Coherent announced two significant strategic developments. In a move to sharpen its focus on core markets and reduce debt, the company agreed to sell its Aerospace and Defence business to private equity firm Advent for $400 million. Potentially more impactful was the expansion of its existing partnership with tech giant Apple. A new multi-year contract ensures Coherent will remain a key supplier, providing VCSEL lasers for Face ID systems manufactured at its Sherman, Texas facility.

Should investors sell immediately? Or is it worth buying Coherent?

Analyst Confidence Remains High

The near-term disappointment did little to dampen the long-term optimism from market analysts. Several firms reaffirmed or raised their positive ratings, indicating strong belief in Coherent’s strategic direction. Stifel increased its price target from $100 to $118 while maintaining a Buy recommendation. Raymond James was even more bullish, boosting its target from $120 to $134 and reiterating a Strong Buy rating. This sentiment was echoed by Rosenblatt ($135 target) and Needham ($120 target), which both confirmed their Buy endorsements. The average analyst price target now stands at $110, signaling a moderate Buy consensus.

The central question remains whether Coherent can translate its strategic positioning into sustained performance that meets these high expectations. The foundation has been laid; the company must now execute.

Ad

Coherent Stock: Buy or Sell?! New Coherent Analysis from February 8 delivers the answer:

The latest Coherent figures speak for themselves: Urgent action needed for Coherent investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 8.

Coherent: Buy or sell? Read more here...

Tags: Coherent
Dieter Jaworski

Dieter Jaworski

About Dieter Jaworski From a numbers-obsessed child to creating his first investment newsletter. Even as a child, Dieter Jaworski's mother couldn't believe how fascinated he was with numbers. This early passion for mathematics and data analysis laid the foundation for a successful career in financial markets and investment analysis.
Areas of Expertise:
  • Quantitative Analysis
  • Financial Newsletter Publishing
  • Data-Driven Investment Strategies
  • Market Pattern Recognition
Dieter's unique approach combines his natural affinity for numbers with decades of market experience, providing investors with data-driven insights and practical investment strategies.

Related Posts

Puma Biotechnology Stock
Earnings

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

February 8, 2026
Quanterix Stock
Analysis

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Next Post
Opendoor Stock

Leadership Shakeup Ignites Historic Rally for Opendoor Stock

Apple Stock

Apple Shares Face Post-Event Selloff as Investors Express Disappointment

Red Cat Stock

Red Cat Shares Surge on NATO Contract Speculation

Recommended

Biotechnology Stock Exchange

Analysts Bullish on Dynatrace with Price Targets on the Rise

2 years ago
The Trade Desk Stock

The Trade Desk Faces Mounting Pressure as Amazon Strikes Netflix Deal

5 months ago

Analyst Reaffirms Buy Rating on International Seaways with 66 Price Target

2 years ago
Biotechnology Stock Bull Market

KeyBanc Analyst Raises Price Target and Maintains Overweight Rating on Repligen NASDAQ RGEN

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Trending

Puma Biotechnology Stock
Earnings

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

by Jackson Burston
February 8, 2026
0

Investor attention is now firmly fixed on February 26, 2026, as Puma Biotechnology prepares to release its...

Quanterix Stock

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Puma Biotechnology Sets Date for Full-Year Financial Disclosure
  • Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test
  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com